跳至主要内容
临床试验/TCTR20190329001
TCTR20190329001已完成1 期

The Effectiveness of Adding Magnesium Sulfate to Tincture of Opium and Buprenorphine on Pain and Quality of Life in Women with Dysmenorrhea: a Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical, the Results of a Six-Month Follow-up

/A0 个研究点目标入组 163 人开始时间: 2019年3月29日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
163

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
Female

入选标准

  • The inclusion criteria were: aged 18-45 years, the presence of regular menstrual cycle, features of pelvic endometriosis (posterior, middle and anterior compartments) and/ or adenomyosis according to the revised American Society for Reproductive Medicine (ASRM) classification and the presence of ovarian endometrioma or uterine adenomyosis at clinical and transvaginal ultrasound (TV-US), taking 2-4 cc of TOP and 2-4 mg Buprenorphine Sublingual.

排除标准

  • Exclusion criteria were: Hypersensitivity to magnesium sulfate, 18>BMI>35, previous surgical treatment, hormonal therapy in the last 6 months, use of drugs affecting Neuromuscular Function, history of renal disease, hepatitis, current pregnancy, major medical illnesses, Spinal disease, neuropathy, hypomagnesemia (serum magnesium concentration < 1.8 mg/dL); hypermagnesemia (serum magnesium concentration> 2.6 mg/dL); taking Calcium-channel blockers (CCBs), AV block degree II or III, systolic blood pressure < 90 mmHg, body temperature > 38 °C, history of heart disease, Liver failure, respiratory disease, renal failure, gastrointestinal bleeding, metabolic disorder, active peptic ulcer, and seizure.

研究者

发起方
/A

相似试验